Crinetics Pharmaceuticals, Inc.
US ˙ NasdaqGS ˙ US22663K1079

SecurityCRNX / Crinetics Pharmaceuticals, Inc.
InstitutionAlps Advisors Inc
Latest Disclosed Ownership85,232 shares
Latest Disclosed Value $ 3,095,626
Alps Advisors Inc reports 9.60% increase in ownership of CRNX / Crinetics Pharmaceuticals, Inc.

On May 8, 2026 - Alps Advisors Inc filed a 13F-HR form disclosing ownership of 85,232 shares of Crinetics Pharmaceuticals, Inc. (US:CRNX) valued at $3,095,626 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 12, 2026 disclosing 77,765 shares of Crinetics Pharmaceuticals, Inc.. This represents a change in shares of 9.60% during the quarter. The current value of the position is $2,805,837 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 85,232 7,467 9.60 3,096 -14.48 0.0134
2026-02-12 2025-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 77,765 30,350 64.01 3,620 83.33 0.0211
2025-11-05 2025-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 47,415 -3,109 -6.15 1,975 35.86 0.0110
2025-08-11 2025-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 50,524 -16,779 -24.93 1,453 -35.62 0.0084
2025-04-30 2025-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 67,303 -7,682 -10.24 2,257 -41.12 0.0131
2025-02-13 2024-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 74,985 14,242 23.45 3,834 23.53 0.0242
2024-11-12 2024-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 60,743 -782 -1.27 3,104 12.63 0.0208
2024-08-13 2024-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 61,525 6,556 11.93 2,756 7.07 0.0189
2024-05-14 2024-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 54,969 8,944 19.43 2,573 57.18 0.0182
2024-02-14 2023-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 46,025 5,697 14.13 1,638 36.53 0.0129
2023-11-14 2023-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 40,328 618 1.56 1,199 67.69 0.0100
2023-08-14 2023-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 39,710 4,190 11.80 716 25.44 0.0062
2023-05-10 2023-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 35,520 -957 -2.62 570 -14.54 0.0050
2023-02-14 2022-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 36,477 7,151 24.38 668 15.80 0.0060
2022-11-14 2022-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 29,326 -2,414 -7.61 576 -2.70 0.0054
2022-08-15 2022-06-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 31,740 -17,075 -34.98 592 -44.72 0.0058
2022-08-11 2022-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 31,740 -17,075 592 0.0057
2022-05-16 2022-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 48,815 -6,149 -11.19 1,071 -31.43 0.0116
2022-02-09 2021-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 54,964 7,528 15.87 1,562 56.36 0.0176
2021-11-15 2021-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 47,436 -2,080 -4.20 999 7.07 0.0096
2021-08-11 2021-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 49,516 -10,047 -16.87 933 2.53 0.0083
2021-05-07 2021-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 59,563 126 0.21 910 8.46 0.0089
2021-02-03 2020-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 59,437 17,503 41.74 839 27.70 0.0094
2020-11-05 2020-09-30 13F/A-1 CRINETICS PHARMACEUTICALS IN COM 22663K107 41,934 -2,875 -6.42 657 -16.31 0.0097
2020-11-04 2020-09-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 41,934 -2,875 657 8,420.2421
2020-08-05 2020-06-30 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 44,809 769 1.75 785 21.33 0.0105
2020-05-06 2020-03-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 44,040 -5,132 -10.44 647 -47.57 0.0100
2020-02-07 2019-12-31 13F CRINETICS PHARMACEUTICALS IN COM 22663K107 49,172 955 1.98 1,234 70.21 0.0096
2019-11-04 2019-09-30 13F CRINETICS PHARMA COMMON STOCK 22663K107 48,217 -2,308 -4.57 725 -42.60 0.0056
2019-08-07 2019-06-30 13F CRINETICS PHARMA COMMON STOCK 22663K107 50,525 50,525 1,263 0.0093
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.